BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 26787504)

  • 1. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
    Park WC; Jordan VC
    Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of breast cancer.
    Thomsen A; Kolesar JM
    Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
    Mocellin S; Pilati P; Briarava M; Nitti D
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in breast cancer chemoprevention.
    Chlebowski RT
    Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
    Dhingra K
    Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
    Johansen AM
    Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
    Vogel VG
    Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.